55545-80-7 Usage
General Description
2-(Dimethylamino)-6-(trifluoromethyl)-4-pyrimidinol is a chemical compound with the molecular formula C8H9F3N4O. It is a pyrimidine derivative that contains a trifluoromethyl group and a dimethylamino group. 2-(DIMETHYLAMINO)-6-(TRIFLUOROMETHYL)-4-PYRIMIDINOL is often used as an intermediate in the synthesis of pharmaceutical products and agricultural chemicals. It has also been studied for its potential use as a fluorescent probe for the detection of metal ions. 2-(Dimethylamino)-6-(trifluoromethyl)-4-pyrimidinol may also have potential applications in the field of organic electronics and materials science due to its unique chemical structure and properties.
Check Digit Verification of cas no
The CAS Registry Mumber 55545-80-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,5,4 and 5 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 55545-80:
(7*5)+(6*5)+(5*5)+(4*4)+(3*5)+(2*8)+(1*0)=137
137 % 10 = 7
So 55545-80-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H8F3N3O/c1-13(2)6-11-4(7(8,9)10)3-5(14)12-6/h3H,1-2H3,(H,11,12,14)
55545-80-7Relevant articles and documents
Synthesis of novel strobilurin-pyrimidine derivatives and their antiproliferative activity against human cancer cell lines
Chai, Baoshan,Wang, Shuyang,Yu, Wenquan,Li, Huichao,Song, Chuanjun,Xu, Ying,Liu, Changling,Chang, Junbiao
supporting information, p. 3505 - 3510 (2013/07/28)
A series of new strobilurin-pyrimidine analogs were designed and synthesized based on the structures of our previously discovered antiproliferative compounds I and II. Biological evaluation with two human cancer cell lines (A549 and HL60) showed that most of these compounds possessed moderate to potent antiproliferative activity. Two potent candidates (8f, IC50 = 2.2 nM and 11d, IC50 = 3.4 nM) were identified with nanomolar activity against leukemia cancer cell line HL60 for further development. This activity represents a 1000- to 2500-fold improvement compared to the parent compounds I and II and is 20- to 30-fold better than the chemotherapy drug, doxorubicin. The present work provides strong incentive for further development of these strobilurin-pyrimidine analogs as potential antitumor agents for the treatment of leukemia.
